Cosentyx is set to change the landscape of the psoriasis market following results...
Evidera and CSS partner on patient-centric research development
Evidera has reached an exclusive collaboration agreement with Shin Nippon Biomedical Laboratories’ (SNBL) subsidiary Clinical Study Support (CSS) to jointly deliver more consulting and analytical capabilities for clinical research.
Lilly’s Taltz meets Phase IV plaque psoriasis trial endpoints
Eli Lilly has reported that the Phase IV IXORA-R clinical trial of Taltz (ixekizumab) met the primary and key secondary endpoints up to week 12.
Akari Therapeutics reports positive data for nomacopan
Akari Therapeutics has reported positive results from an ongoing Phase II clinical trial assessing nomacopan for the treatment of an autoimmune inflammatory skin disease called bullous pemphigoid (BP).
MC2 Therapeutics enrols patents for trial of MC2-01 PAD Cream
MC2 Therapeutics has completed enrollment for its Phase III study of MC2-01 PAD Cream to treat adult patients with plaque psoriasis.
Phase III trial of Dupixent meets primary and secondary endpoints
A pivotal Phase III trial of Sanofi and Regeneron’s Dupixent (dupilumab) to treat severe atopic dermatitis in children aged six to 11 years has met its primary and secondary endpoints.
Trials data suggests Cosentyx from Novartis will change psoriasis market
Cosentyx is set to change the landscape of the psoriasis market following results published by Novartis from a phase II study,
Incyte reports positive results from trial of ruxolitinib to treat vitiligo
Incyte has reported positive results from a Phase II trial of ruxolitinib cream for the treatment of adult patients aged 18 to 75 with vitiligo, a chronic, immune-mediated skin disease.
Skyrizi (risankizumab-rzaa) for the Treatment of Plaque Psoriasis
Skyrizi™ (risankizumab-rzaa) is a monoclonal antibody (mAb) indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients.
Pfizer’s abrocitinib meets goals in atopic dermatitis trial
Pfizer has reported positive top-line data from a Phase III clinical trial of its abrocitinib (PF-04965842), which met the primary and key secondary endpoints in moderate to severe atopic dermatitis (AD) patients aged 12 and older.
MorphoSys and Galapagos launch Phase II atopic dermatitis trial
MorphoSys and Galapagos have commenced a Phase II clinical trial, in alliance with Novartis Pharma, to assess subcutaneous MOR106 in combination with topical corticosteroids to treat moderate to severe atopic dermatitis.